key: cord-0269824-hkbm7eyp authors: Barreiro, N.; Govezensky, T.; Ventura, C.; Nunez, M.; Bolcatto, P.; Barrio, R. title: Modelling the interplay of SARS-CoV-2 variants in the United Kingdom. date: 2021-11-28 journal: nan DOI: 10.1101/2021.11.26.21266485 sha: 4b32b56b3334262a0c97458b9a4e891e25dcbc6d doc_id: 269824 cord_uid: hkbm7eyp Most COVID-19 vaccines have proved to be effective to combat the pandemic and to prevent severe disease but their distribution proceeds in a context of global vaccine shortage Their uneven distribution favors the appearance of new variants of concern, as the highly transmissible Delta variant, affecting especially non-vaccinated people. We consider that devising reliable models to analyse the spread of the different variants is crucial. These models should include the effects of vaccination as well as non-pharmaceutical measures used to contain the pandemic by modifying social behaviour. In this work, we present a stochastic geographical model that fulfills these requirements. It consists of an extended compartmental model that includes various strains and vaccination strategies, allowing to study the emergence and dynamics of the new COVID-19 variants. The models conveniently separates the parameters related to the disease from the ones related to social behavior and mobility restrictions. The geographical spread of the virus is modeled taking into account the actual population distribution in any given country of interest. Here we choose the UK as model system, taking advantage of the reliable available data, in order to fit the recurrence of the currently prevalent variants. Our computer simulations allow to describe some global features observed in the daily number of cases, as the appearance of periodic waves and the features that determine the prevalence of certain variants. They also provide useful predictions aiming to help planning future vaccination boosters. We stress that the model could be applied to any other country of interest. The SARS-CoV-2 virus pandemic has infected more than 242 million people worldwide, with more than 4.9 million global Susceptible, Recovered, Vaccinated, Exposed and Infected with different strains, are taken into account. Vaccinated people can get infected with a certain variant k with a γ k probability. The exposed, infectious and immune periods for the k − th strain are ε k , σ k and ω k , respectively. The variables v r and δ stand for the vaccination rate and the immunity period conferred by the vaccine. (B) The global dynamics on a geographical area, divided into a grid of cells, is followed by placing a SEIRS-V model on each one and allowing contagions between them . Three mobility processes are considered: movement to neighbor and far cells and thermal noise. actual properties of each strain with the available data. Vaccination effects are also taken into account in order to study its 17 effectiveness under scenarios with different strains. 18 The model used in this work is an extension of the one presented by Barreiro et al. 17 , in order to include the emergence of 19 new virus variants at different times. The map of the country being studied is divided in a two-dimensional grid in which the 20 dynamics occurs. We use a modified SEIRS-V model to simulate the local dynamics (see Fig. 1 (A)) of infection spreading, 21 taking place in each cell (i, j) of an area of a few km 2 , with average population density ρ(i, j). Global dynamics ( Fig. 1(B) ), 22 comprising the entire country, considers geographical spread to neighboring cells and along terrestrial roads or aerial routes; 23 governmental non-pharmaceutical interventions, and social behavior are reflected in the mobility parameters used (v). 24 Description of the local dynamics. The compartmental model includes: susceptible (S), exposed to the different variants 25 present in the location, yet not infective (E k , k = 1,. . . ,N), after ε k days people become infective and can transmit the variant 26 with which they got infected (I k , k = 1,. . . ,N), they stay infective σ k days and recover (R); acquired immunity lasts for ω k days 27 and then, a proportion z k of people who survived, become susceptible again (S). At a specific time, vaccination designed to 28 protect from the initial variant started, being applied at a rate v r ; vaccinated people (V ) stay immune for δ days but, with a 29 probability γ k , they may be infected with variant k (fig 1(A) ). Description of the global dynamics. Geographical spread ( Fig. 1 (B) ) is simulated by using mobility parameters: ν n for 31 movement between neighbor cells, and ν a for long distance trips by airplane, car, or train. We consider that flows between large 32 cities are greater than flows between small ones, therefore, ν a is weighted by ρ(i, j)ρ(m, n) i.e. by the origin and destination 33 population densities. All mobility parameters 0 < ν < 1, interpreted as the probability of traveling from one cell, in which 34 I k (i, j,t) ≥ η, to another cell, are modeled by a Metropolis Monte-Carlo algorithm (for details see Appendix). In the newly 35 infected cell S(m, n,t) = 1 − η and I k (m, n,t) = η. The epidemic reaches unexpected places because people sporadically travel to remote places, regardless of their population, 37 these random movements may be considered as "kinetic energy" kT of the system. In this case we use a Monte-Carlo procedure 38 comparing a random number with the quantity exp(−kT ). Interaction between variants can be included in our model, but until now, very few cases of co-infection with two COVID-19 40 variants have been reported, so we decided not to include possible interactions in this paper. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The model was applied to the case of the United Kingdom (UK). As stated above, to apply the model to a specific country data 42 about its population density is required. The information to generate the density map was extracted from the "Global High 43 Resolution Population Denominators Project" 18 . The main routes were obtained from Google Maps. In order to compute the 44 geo-stochastic spreading of the virus, the map was divided into a grid of squares of 25 km 2 (see Fig. 2 ). Table 1 shows the values of the parameters used in order to make the calculations. The vaccination rate v r was fitted over time in order to adjust the model to the real immunization data (delayed 14 days 53 to ensure immunity development). Vaccination and daily cases data were obtained from "Our World in Data" 2, 21 and Johns 54 Hopkins University 1 . 66% of the population was fully vaccinated by the end of September. Taking into account the willingness 55 3/9 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 28, 2021. ; https://doi.org/10.1101/2021.11.26.21266485 doi: medRxiv preprint to be vaccinated 2, 21 in the United Kingdom, however, it is not expected that a large population group will be vaccinated after that. For simplicity, in the model we consider that 70% of the population will be immunized. 57 We used the stringency index 22 (a measure of the severity of government policies during the pandemic) as a guide to fit 58 mobility ν over time. In order to reduce the amount of fitting parameters we employed the same value of ν for both neighbor 59 and far mobility (the latter was weighted by the origin and destination densities). Mobility was adjusted up to August 15, 60 2021, leaving the same value from then on. Any change in government policies, increasing or decreasing restrictions, could 61 produce a modification of the results. kT was left on a low level (0.1) since, from the beginning of the pandemic, there have 62 been multiple measures to reduce mobility (internal restrictions and bans or quarantine for travellers entering the UK from 63 high-risk regions) 2, 22 . The parameter β k , which reflects how contagious a strain is, was changed to fit the actual curves for each 64 variant. As we mentioned before, new variants could be more contagious 6, 7 and dominate over previous ones. In this sense, 65 β k determines how variants will compete and dominate over time. The lower panel on Table 1 shows the fitted β k values for 66 each strain. At the same time, some vaccines have exhibited a lower effectiveness against some variants 23 . To take this into 67 account we used the γ k parameter. Given a k − th strain, the higher γ k , the more likely that a vaccinated person will get infected 68 by it. Some parameters such as the period of immunity conferred by the vaccine and the efficiency for some variants still need 69 further study. We emphasize here that the immunity period that the vaccines provide, together with the inherent efficiency of 70 the vaccines are the important factors to be considered. Therefore, we decided to propose three possible different scenarios: Table 1 . The inset in the figure shows the fraction of infections with each variant. In order to fit the fast case growth of the delta variant 77 (which cannot be explained only in terms of mobility changes) we had to use a very high β delta value and a lower value of 78 ε delta (0) (see Table 1 ). In order to remark the evolution of the Delta variant, in this inset, we show a longer time period. From 79 the Fig. 3 (A) it is clear that at the current transmission rate this strain will dominate over the others and, unless a new, more 80 contagious, variant appears, it will prevail in the near future. Figure 3 (B) shows immunization as a function of time. In this case 81 the vaccination rate was changed on the model to fit the actual data with a delay of 14 days. This delay was added to ensure that 82 fully vaccinated people reach actual immunization. The dashed orange curve represent official data while the red solid line 83 corresponds to the model immunization progress. As mentioned before, vaccination stops when 70% population is reached. The model applied to the second scenario is shown in red. As we mentioned before, the model was conceived with the 91 assumption that if a person presents a breakthrough infection, his/her immune system is boosted and therefore he/she will 92 remain immune δ additional days after infection. This assumption is sensible, given the abundant evidence of increased 93 antibody levels when a previously infected person is vaccinated [24] [25] [26] . This is clearly shown by the model dynamics in Fig. 4 . In . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 28, 2021. ; proteins. However, mass vaccination is clearly the key to reduce the appearance of new variants of concern and, consequently, 111 the need of those specific shots. There is currently a huge debate in the world on this matter [27] [28] [29] . If vaccinated people get 112 a mild version of the infection, COVID-19 will turn out to be a common, relatively harmless, influenza-like disease and (as 113 shown in our model) there will be less susceptible people over time. Under this assumptions, mobility restrictions should be 114 applied mainly to contain the spread of new variants of concern and boosters should only be given to high risk groups in the 115 near future. Long-term booster vaccination is a different discussion to be considered, as there is no information on the duration 116 of its immunity yet. The results of the present study seem to imply that the world's population would probably need to be 117 vaccinated periodically in the years to come. Given the global impact of the COVID-19 pandemic, reliable models to analyze the virus propagation, including the variants 119 of concern, are crucial to explore effective mitigation strategies. Our geo-stochastic multi-variant SEIRS-V model provides In the present work, we applied the model to the UK, and found that it successfully describes the dynamics of the pandemic. Notice that it was essential to fit variant-dependant epidemiological parameters like the transmission coefficients (β k ) for 128 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 28, 2021. ; , respectively. Shaded areas on each color represent the standard deviation from 100 model runs for each scenario. Yellow dash-dot vertical line indicates the day when immunization started. Blue bars and solid orange lines are the actual daily cases and their 7 day rolling average, respectively. In scenario 1, a short vaccination immunity period implies a growth of the daily cases in the near future, if current mobility is sustained. Under scenario 2, people are expected to be immune for a longer time and breakthrough infections will act as antibodies boosters, prolonging the defence against the pandemic. In scenario 3 most people will be immune in the near future, lowering the number of cases, and a new wave would appear when vaccine immunity ends. the Alpha and Delta variants of the disease. We identified the epidemiological parameters which determine the dominant 129 variant: the one possessing larger transmission coefficient (β ) or smaller exposed period (ε) will eventually become dominant. Interestingly, as new variants with higher transmission coefficient appear, they quickly become the prevalent strain. 131 We emphasise that the model is applicable to any country with reliable data, as shown here for UK with the main variants of 132 concern, and previously for Finland, Iceland, Mexico, Spain and Argentina [15] [16] [17] . The social parameters included in the model, 133 as the different mobility types, allow to distinguish the effects of behavioural and cultural differences. For Spain and Argentina 134 good fittings were obtained with the same biological parameters as in the UK (not presented here). 135 Furthermore, this model is useful to predict future scenarios, testing pharmaceutical and non-pharmaceutical interventions, 136 and in particular to optimize the timing of vaccination boosters in order to minimize the appearance of new waves of the disease. When vaccinated individuals get infected (with probability γ k ), the immune system is boosted by the presence of the virus, we 145 therefore assume they will remain immune δ additional days after they got infected. Products in this V compartment track the 146 timing of losing immunity of this individuals. The dynamical model equations for each cell are described by the following mathematical map, 148 6/9 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 28, 2021. ; https://doi.org/10.1101/2021.11.26.21266485 doi: medRxiv preprint Along the simulation, population is considered to be constant, At local level, people do not only follow a daily routine but they may also visit unpredictable places. A local mobility 159 parameter 0 < ν L < 1 depicts this fact, adding randomness to cell dynamics. ν L is compared with a random number (r) from a 160 uniform distribution, if ν L ≤ r the epidemics in the cell proceeds, else no new cases are added in this cell this particular day. Global dynamics. Traditional models use diffusion to model geographical spread of epidemics; we use a Metropolis Monte-Carlo algorithm to simulate mobility between cells. Although we described three different mobility parameters (ν L , ν n 163 and ν a ), for simplicity we consider ν L = ν n = ν a = ν, and 0 < ν < 1. In the case of neighbor cells, we localize cells where 164 I k (i, j,t) ≥ η, then if ν ≤ r, the infections spreads to the neighboring cell (i,j+1,t) where S(i, j + 1,t) becomes 1 − η and 165 I k (i, j + 1,t) = η; (r is a random number from a flat distribution, η is a parameter related to the infectiousness of the disease). For long distance dispersal, the amount of travels affects the probability of spreading disease; to estimate this movement we 167 consider that people travel more from/to large cities than from/to small ones, therefore, for long distance transmission from cell 168 (i,j) where I k (i, j,t) ≥ η to cell (m,n), if ρ(i, j)ρ(m, n)ν ≤ r then S(m, n,t) = 1 − η and I k (m, n,t) = η. An interactive web-based dashboard to track COVID-19 in real time Coronavirus pandemic (COVID-19) World Health Organization. The effects of virus variants on COVID-19 vaccines COVID-19 Genomics UK Consortium. COG-UK / mutation explorer The coronavirus is mutating -does it matter? Understanding variants of SARS-CoV-2 Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study World Health Organization Sensitivity of SARS-CoV-2 B.1.1.7 to mrna vaccine-elicited antibodies Genomic evidence for reinfection with SARS-CoV-2: a case study Dynamics of a dual SARS-CoV-2 lineage co-infection on a prolonged viral shedding COVID-19 case: Insights into clinical severity and disease duration SARS-CoV-2 variants and ending the COVID-19 pandemic. The Lancet Modelling the geographical spread of the influenza pandemic a(h1n1): The case of mexico A model for social spreading of COVID-19: the case of mexico, finland and iceland. Phys. A 582 Detecting infected asymptomatic cases in a stochastic model for spread of Covid-19. The case of Argentina Strategies for COVID-19 vaccination under a shortage scenario: a geo-stochastic modelling approach Funded by The Bill Melinda Gates Foundation (OPP1134076) Sch. Geogr Covariants: SARS-CoV-2 mutations and variants of interest Data, disease and diplomacy: Gisaid's innovative contribution to global health Data. Coronavirus (COVID-19) vaccinations A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker) Impact of delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. medRxiv Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination World Health Organization. Interim statement on COVID-19 vaccine booster doses Considerations in boosting COVID-19 vaccine immune responses. The Lancet COVID vaccine boosters: the most important questions RAB, MN and NLB acknowledge support from The National Autonomous University of Mexico (UNAM) and Alianza UCMX of the University of California (UC), through the project included in the Special Call for Binational Collaborative Projects addressing COVID-19. RAB was financially supported by Conacyt through project 283279 and PAPIIT, UNAM project IG200121. MN was partially supported by CONICET. NLB and PGB acknowledge support from project 03 NAC 009/21 from CITEDEF. We acknowledge the researchers and laboratories responsible for obtaining the specimens, generating the genetic sequence and metadata and sharing via the GISAID Initiative. The authors declare no competing interests.